HVIA
HZNP

Hudson Valley Investment Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Hudson Valley Investment Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-4,000
Closed -$411K – 203
2023
Q2 		$411K Hold
4,000
– – 0.06% 150
2023
Q1 		$437K Hold
4,000
– – 0.06% 156
2022
Q4 		$455K Buy
+4,000
New +$332K 0.07% 147

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Hudson Valley Investment Advisors's HZNP Position: Q3 2023 in Review

Hudson Valley Investment Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 4,000 shares — an estimated $411K sold.

Hudson Valley Investment Advisors first reported a position in HZNP in Q4 2022 and held it in 3 quarters. The position peaked at $455K in Q4 2022. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

  • Hudson Valley Investment Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
  • Hudson Valley Investment Advisors sold 4,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $411K.
  • Hudson Valley Investment Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2022 and held it in 3 quarters.
  • Hudson Valley Investment Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $455K in Q4 2022.
  • 485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on Hudson Valley Investment Advisors's 13F filing for Q3 2023, filed 27 Oct 2023.